Abstract
Anorexia nervosa is a debilitating psychiatric disorder characterized by severe dietary restriction and lifethreatening weight loss. The onset of the disorder typically occurs during adolescence with 90-95% of all cases occurring in females. Often characterized by a chronic and relapsing course, anorexia nervosa has one of the highest mortality rates of any psychiatric disorder. Although the etiology is unknown, a complex interplay of genetic, neurobiological, and environmental variables appear to factor into the development of the disorder. Accumulating evidence supports altered serotonin 5-HT1A, 5-HT2A, and 5-HTT receptor binding in anorexia nervosa, with more recent studies examining dopamine D2/D3 receptor binding. Despite this increasing knowledge of neurotransmitter alterations, there are few effective treatment strategies, with pharmacological treatments having minimal efficacy during the acute phase of illness. Thus, the goal of this paper is to provide an overview of neurochemical alterations during the ill state and following long-term recovery. This will be followed by a review of pharmacological treatment studies of anorexia nervosa that will focus on the limited efficacy of SSRIs and more promising findings from atypical antipsychotics. Given the combination of receptors targeted by newer generation atypical antipsychotics, these drugs may provide a more efficient means for modulating the neurobiological disturbances seen in anorexia nervosa.
Keywords: Serotonin 5-HT, positron emission tomography (PET), Dopamine receptor, Antipsychotics, Selective Serotonin Reuptake Inhibitors
Central Nervous System Agents in Medicinal Chemistry
Title: Neurochemistry and Pharmacological Treatments: Where is the Field of Anorexia Nervosa Heading?
Volume: 7 Issue: 1
Author(s): Nicole C. Barbarich-Marsteller
Affiliation:
Keywords: Serotonin 5-HT, positron emission tomography (PET), Dopamine receptor, Antipsychotics, Selective Serotonin Reuptake Inhibitors
Abstract: Anorexia nervosa is a debilitating psychiatric disorder characterized by severe dietary restriction and lifethreatening weight loss. The onset of the disorder typically occurs during adolescence with 90-95% of all cases occurring in females. Often characterized by a chronic and relapsing course, anorexia nervosa has one of the highest mortality rates of any psychiatric disorder. Although the etiology is unknown, a complex interplay of genetic, neurobiological, and environmental variables appear to factor into the development of the disorder. Accumulating evidence supports altered serotonin 5-HT1A, 5-HT2A, and 5-HTT receptor binding in anorexia nervosa, with more recent studies examining dopamine D2/D3 receptor binding. Despite this increasing knowledge of neurotransmitter alterations, there are few effective treatment strategies, with pharmacological treatments having minimal efficacy during the acute phase of illness. Thus, the goal of this paper is to provide an overview of neurochemical alterations during the ill state and following long-term recovery. This will be followed by a review of pharmacological treatment studies of anorexia nervosa that will focus on the limited efficacy of SSRIs and more promising findings from atypical antipsychotics. Given the combination of receptors targeted by newer generation atypical antipsychotics, these drugs may provide a more efficient means for modulating the neurobiological disturbances seen in anorexia nervosa.
Export Options
About this article
Cite this article as:
Barbarich-Marsteller C. Nicole, Neurochemistry and Pharmacological Treatments: Where is the Field of Anorexia Nervosa Heading?, Central Nervous System Agents in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/187152407780059204
DOI https://dx.doi.org/10.2174/187152407780059204 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Using Small Peptide Segments of Amyloid-β and Humanin to Examine their Physical Interactions
Protein & Peptide Letters Role of Vitamin D in Autism Spectrum Disorder
Current Pharmaceutical Design Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers
Current Psychiatry Reviews P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Imidazoline Receptors, Novel Agents and Therapeutic Potential
Cardiovascular & Hematological Agents in Medicinal Chemistry Microwave Induced Center-Doping of Transition Metals Ions in Aqueous CdS NCs with Special Optical Properties
Current Microwave Chemistry Protein Kinase C Modulates Aurora-kinase Inhibition Induced by CCT129202 in HMC-1560,816 Cell Line
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Physiological Roles of Glycogen Synthase Kinase-3: Potential as a Therapeutic Target for Diabetes and Other Disorders
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer
Current Topics in Medicinal Chemistry <i>Lepidium meyenii</i> Supplemented Diet Modulates Neurobehavioral and Biochemical Parameters in Mice Fed High-Fat High-Sugar Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Current Cancer Drug Targets SUBJECT INDEX TO VOLUME 1
Current Drug Safety The Toxicogenetics of Antirretroviral Therapy: The Evil Inside
Current Medicinal Chemistry Changes in Cognition, Depression and Quality of Life after Carotid Stenosis Treatment
Current Neurovascular Research New Approaches for the Treatment of Mental Disorders Comorbid with Inflammatory Diseases
Current Topics in Medicinal Chemistry Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research